company background image
688336 logo

Sunshine Guojian Pharmaceutical (Shanghai) SHSE:688336 Stock Report

Last Price

CN¥18.20

Market Cap

CN¥11.2b

7D

10.1%

1Y

-15.9%

Updated

16 Sep, 2024

Data

Company Financials +

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd

SHSE:688336 Stock Report

Market Cap: CN¥11.2b

688336 Stock Overview

A biopharmaceutical company, engages in the research and development, manufacturing, and commercialization of antibody drugs in China.

688336 fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance4/6
Financial Health5/6
Dividends0/6

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Sunshine Guojian Pharmaceutical (Shanghai)
Historical stock prices
Current Share PriceCN¥18.20
52 Week HighCN¥26.78
52 Week LowCN¥15.22
Beta0.26
11 Month Change0.44%
3 Month Change-18.57%
1 Year Change-15.90%
33 Year Change-8.54%
5 Year Changen/a
Change since IPO-66.36%

Recent News & Updates

What Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd's (SHSE:688336) P/E Is Not Telling You

Jul 25
What Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd's (SHSE:688336) P/E Is Not Telling You

Is Sunshine Guojian Pharmaceutical (Shanghai) (SHSE:688336) A Risky Investment?

Jun 20
Is Sunshine Guojian Pharmaceutical (Shanghai) (SHSE:688336) A Risky Investment?

If EPS Growth Is Important To You, Sunshine Guojian Pharmaceutical (Shanghai) (SHSE:688336) Presents An Opportunity

May 24
If EPS Growth Is Important To You, Sunshine Guojian Pharmaceutical (Shanghai) (SHSE:688336) Presents An Opportunity

Recent updates

What Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd's (SHSE:688336) P/E Is Not Telling You

Jul 25
What Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd's (SHSE:688336) P/E Is Not Telling You

Is Sunshine Guojian Pharmaceutical (Shanghai) (SHSE:688336) A Risky Investment?

Jun 20
Is Sunshine Guojian Pharmaceutical (Shanghai) (SHSE:688336) A Risky Investment?

If EPS Growth Is Important To You, Sunshine Guojian Pharmaceutical (Shanghai) (SHSE:688336) Presents An Opportunity

May 24
If EPS Growth Is Important To You, Sunshine Guojian Pharmaceutical (Shanghai) (SHSE:688336) Presents An Opportunity

We Think That There Are Issues Underlying Sunshine Guojian Pharmaceutical (Shanghai)'s (SHSE:688336) Earnings

Mar 31
We Think That There Are Issues Underlying Sunshine Guojian Pharmaceutical (Shanghai)'s (SHSE:688336) Earnings

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd (SHSE:688336) Stock Rockets 26% As Investors Are Less Pessimistic Than Expected

Mar 04
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd (SHSE:688336) Stock Rockets 26% As Investors Are Less Pessimistic Than Expected

Shareholder Returns

688336CN BiotechsCN Market
7D10.1%-2.6%-1.3%
1Y-15.9%-29.3%-21.4%

Return vs Industry: 688336 exceeded the CN Biotechs industry which returned -28.5% over the past year.

Return vs Market: 688336 exceeded the CN Market which returned -21.1% over the past year.

Price Volatility

Is 688336's price volatile compared to industry and market?
688336 volatility
688336 Average Weekly Movement6.3%
Biotechs Industry Average Movement5.8%
Market Average Movement5.4%
10% most volatile stocks in CN Market8.6%
10% least volatile stocks in CN Market3.6%

Stable Share Price: 688336's share price has been volatile over the past 3 months.

Volatility Over Time: 688336's weekly volatility (6%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2002964n/awww.3s-guojian.com

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd, a biopharmaceutical company, engages in the research and development, manufacturing, and commercialization of antibody drugs in China. Its products include YISAIPU, a tumor necrosis factor inhibitor type II-antibody fusion protein for the treatment of autoimmune rheumatism and immunology; Septin, an initututab for injection; and Xenipax, a recombinant anti-CD25 humanized monoclonal antibody injection to prevent acute rejection caused by kidney transplantation, as well as used in conjunction with conventional immunosuppression regimens to increase the survival rate of transplanted organs and enhance patients' quality of life. The company is also developing products for autoimmune, oncology, ophthalmological, and other diseases.

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd Fundamentals Summary

How do Sunshine Guojian Pharmaceutical (Shanghai)'s earnings and revenue compare to its market cap?
688336 fundamental statistics
Market capCN¥11.23b
Earnings (TTM)CN¥329.37m
Revenue (TTM)CN¥1.13b

34.1x

P/E Ratio

9.9x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
688336 income statement (TTM)
RevenueCN¥1.13b
Cost of RevenueCN¥262.72m
Gross ProfitCN¥870.12m
Other ExpensesCN¥540.75m
EarningsCN¥329.37m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)0.53
Gross Margin76.81%
Net Profit Margin29.07%
Debt/Equity Ratio1.0%

How did 688336 perform over the long term?

See historical performance and comparison

Dividends

0.4%

Current Dividend Yield

15%

Payout Ratio